Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
Sigurgeirsson B, Schäkel K, Hong CH, Effendy I, Placek W, Rich P, Keefe D, Bruin G, Charef P, Fu R, Hampele I, Patekar M. Sigurgeirsson B, et al. Among authors: fu r. J Dermatolog Treat. 2022 May;33(3):1718-1726. doi: 10.1080/09546634.2021.1902925. Epub 2021 Apr 26. J Dermatolog Treat. 2022. PMID: 33896356 Free article. Clinical Trial.
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
Bruin G, Hockey HP, La Stella P, Sigurgeirsson B, Fu R, Patekar M, Charef P, Woessner R, Boutouyrie-Dumont B. Bruin G, et al. Among authors: fu r. Br J Clin Pharmacol. 2020 Feb;86(2):338-351. doi: 10.1111/bcp.14155. Epub 2020 Jan 7. Br J Clin Pharmacol. 2020. PMID: 31658377 Free PMC article.
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
Sigurgeirsson B, Browning J, Tyring S, Szepietowski JC, Rivera-Díaz R, Effendy I, Keefe D, Bruin G, Paguet B, Fu R, Hampele I, Reinhardt M, Patekar M. Sigurgeirsson B, et al. Among authors: fu r. Dermatol Ther. 2022 Mar;35(3):e15285. doi: 10.1111/dth.15285. Epub 2022 Jan 8. Dermatol Ther. 2022. PMID: 34954841 Clinical Trial.
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Cai L, et al. Among authors: fu r. Chin Med J (Engl). 2020 Nov 20;133(22):2665-2673. doi: 10.1097/CM9.0000000000001163. Chin Med J (Engl). 2020. PMID: 33060370 Free PMC article. Clinical Trial.
3,566 results